Erratum: Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies (Expert Opinion on Drug Safety (2013) 12 (621-629) DOI: 10.1517/14740338.2013.816674);Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies

Expert Opinion on Drug Safety

Volumn 12, Issue 5, 2013, Pages 621-629

  Derosa, Giuseppe ^a   Cicero, Arrigo Francesco Giuseppe ^b   Carbone, Anna ^c   Querci, Fabrizio ^d   Fogari, Elena ^a   D'Angelo, Angela ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Hospital Center of Diabetes   (Italy)

^d Ospedale Pesenti Fenaroli   (Italy)

Author keywords

Amlodipine; Combination therapy; Hypertension; Interleukins; Olmesartan

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS OLMESARTAN; GLUCOSE; HYDROCHLOROTHIAZIDE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 8; LIPID; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OLME AMLO; OLMESARTAN; UNCLASSIFIED DRUG; VASPIN;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DIET; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; EDEMA; EVALUATION; EXERCISE; FASTING PLASMA GLUCOSE; FASTING PLASMA INSULIN; FEMALE; FIXED DRUG ERUPTION; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLYCEMIC CONTROL; HOMA INDEX; HUMAN; HYPERKALEMIA; HYPERTENSION; INDUCED HYPOTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH PAIN; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ADIPOKINES; AMLODIPINE; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-10; INTERLEUKIN-8; LIPIDS; MALE; MIDDLE AGED; TETRAZOLES;

EID: 84882977181     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1090046     Document Type: Erratum

References (39)

1. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275(20):1571-6
2. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755-62
3. Liu L, Zhang Y, Liu G, et al. for the FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebocontrolled trial in Chinese hypertensive patients. J Hypertens 2005;23(12):2157-72
4. Steckelings UM, Rompe F, Kaschina E, Unger T. The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam Clin Pharmacol 2009;23:693-703
5. Mancia G, Laurent S, Agabiti-Rosei E, et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27(11):2121-58
6. Derosa G, Maffioli P, Salvadeo SA, et al. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertens Res 2010;33(8):790-5
7. Derosa G, Maffioli P, Salvadeo SA, et al. Candesartan effect on inflammation in hypertension. Hypertens Res 2010;33(3):209-13
8. Fogari R, Zoppi A, Mugellini A, et al. Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. Expert Opin Pharmacother 2012;13(8):1091-9
9. Fogari R, Zoppi A, Maffioli P, et al. Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. Clin Cardiol 2012;35(6):359-64
10. Miura S, Fujino M, Saku K. Angiotensin II receptor blocker as an inverse agonist: a current perspective. Curr Hypertens Rev 2005;1:115-21
11. Teramoto T, Fujita T, Kawamori R, et al. OMEGA study: design, baseline data, metabolic syndrome prevalence in a large-scale observational study of hypertensive patients: the Olmesartan mega study to determine the relationship between cardiovascular endpoints and blood pressure goal achievement study. Hypertens Res 2008;31:2011-17
12. Derosa G, Maffioli P. Drug safety evaluation of amlodipine. Expert Opin Drug Saf 2011;10(5):795-804
13. Derosa G, Maffioli P. Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. Expert Rev Cardiovasc Ther 2010;8(6):835-43
14. Fogari R, Derosa G, Lazzari P, et al. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am J Hypertens 2004;17(9):823-7
15. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30(4):587-604
16. Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006. Arterioscler Thromb Vasc Biol 2006;26:2186-91
17. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-30
18. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972;8:260-6
19. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19
20. Klose S, Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem 1978;15:121-30
21. Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Bermeyer HU, editor. Methods of enzymatic analysis. 2nd English edition. Academic Press, Inc; New York: 1974. p. 18-31
22. Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
24. Korner A, Garten A, Bluher M, et al. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007;92:4783-91
25. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005;102:10610-15
26. Khan SS, Smith MS, Reda D, et al. Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom 2004;61:35-9
27. De Fronzo RA, Tobin JA, Andres B. Glucose clamp technique, a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:214-23
28. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987;317(6):350-7
29. Winer BJ. Statistical principles in experimental design. 2nd edition. McGraw-Hill, New York; 1971
30. Fogari R, Maffioli P, Mugellini A, et al. Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. Eur J Gastroenterol Hepatol 2012;24(2):164-71
31. Martinez-Martin FJ, Rodriguez-Rosas H, Peiro-Martinez I, et al. Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. J Hum Hypertens 2011;25(6):346-53
32. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-30
33. Hug C, Lodish HF. Visfatin: a new adipokine. Science 2005;307:366-7
34. Fukao K, Shimada K, Hiki M, et al. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function-a crossover trial (AGENT). Cardiovasc Diabetol 2011;10:79
35. Wolff B, Burns AR, Middleton J, Rot A. Endothelial cell "memory" of inflammatory stimulation: human venular endothelial cells store interleukin 8 in Weibel-Palade bodies. J Exp Med 1998;188(9):1757-62
36. Utgaard JO, Jahnsen FL, Bakka A, et al. Rapid secretion of prestored interleukin 8 from Weibel-Palade bodies of microvascular endothelial cells. J Exp Med 1998;188(9):1751-6
37. Groux H, Cottrez F. The complex role of interleukin-10 in autoimmunity. J Autoimmun 2003;20(4):281-5
38. Gurbel PA, Kreutz RP, Bliden KP, et al. Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. Am Heart J 2008;155(1):56-61
39. Mizia-Stec K, Mandecki T, Zahorska-Markiewicz B, et al. Selected cytokines and soluble forms of cytokine receptors in coronary artery disease. Intern Med 2002;13(2):115-22